High-tailored Anal Canal Radiotherapy (HIT-ART): Outcomes of a 10-Year Single Center Clinical Experience

Overview

Journal In Vivo

Specialty Oncology

Date 2024 Apr 30

PMID 38688632

Authors

Stefania Manfrida

Bruno Fionda

Silvia Mariani

Viola De Luca

Roberta Bertolini

Brunella Barbaro

Giuditta Chiloiro

Vincenzo Frascino

Luca Tagliaferri

Maria Antonietta Gambacorta

Affiliations

Soon will be listed here.

Abstract

Background/aim: The current standard for anal cancer treatment is essentially a 'one size fits all' approach where the dose of radiotherapy is similar whether the tumor is very small or very large. Trials are ongoing to evaluate dose de-escalation or escalation in localized disease depending on tumor size. The aim of the study was to assess results of a personalized approach involving dose stratification by stage and boost dose adjusted according to tumor early response.

Patients And Methods: We retrospectively reviewed squamous cell anal cancer (SCAC) patients treated between 2011 and 2021 by long-course intensity-modulated radiotherapy (IMRT) and concomitant chemotherapy (CT); a sequential boost could be administered by IMRT or interventional radiotherapy (IRT) to obtain a total equivalent dose in 2 Gy (EQD2) of 54-60 Gy.

Results: We analyzed 110 patients (61% T3-4 stage, 71% node-positive). A total of 68.2% of patients received a sequential boost, mainly by IRT; median total EQD2 to primary site was 59.3 Gy. Acute ≥G3 toxicity rate was 36.4%. Median follow-up (FUP) was 35.4 months. A total of 83% of patients achieved clinical complete response (cCR); locoregional recurrence (LRR) occurred in 20.9% and distant metastases in 6.4% of cases. A total of 12.7% patients underwent salvage surgery. A total of 25.5% of patients reported ≥G2 and 4.5% ≥G3 late toxicity. The estimated 3-year overall survival, disease-free survival and colostomy-free survival were 92%, 72% and 84% respectively; 3-year-LRR was 22%. Nodal stage was associated with poorer cCR probability and higher LRR (p<0.05).

Conclusion: Our results on a large cohort of patients with locally advanced SCAC and long FUP time confirmed the efficacy of IMRT; high local control and manageable toxicity also suggest IRT as a promising method in treatment personalization.

References

Kovacs G, Tagliaferri L, Valentini V . Is an Interventional Oncology Center an advantage in the service of cancer patients or in the education? The Gemelli Hospital and INTERACTS experience. J Contemp Brachytherapy. 2018; 9(6):497-498. PMC: 5808000. DOI: 10.5114/jcb.2017.72603. View

Shakir R, Adams R, Cooper R, Downing A, Geh I, Gilbert D . Patterns and Predictors of Relapse Following Radical Chemoradiation Therapy Delivered Using Intensity Modulated Radiation Therapy With a Simultaneous Integrated Boost in Anal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2019; 106(2):329-339. PMC: 6961207. DOI: 10.1016/j.ijrobp.2019.10.016. View

Bosset J, Roelofsen F, Morgan D, Budach V, Coucke P, Jager J . Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and.... Eur J Cancer. 2002; 39(1):45-51. DOI: 10.1016/s0959-8049(02)00377-5. View

Glynne-Jones R, Sebag-Montefiore D, Meadows H, Cunningham D, Begum R, Adab F . Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. Lancet Oncol. 2017; 18(3):347-356. PMC: 5337624. DOI: 10.1016/S1470-2045(17)30071-2. View

NIGRO N, SEYDEL H, Considine B, VAITKEVICIUS V, Leichman L, Kinzie J . Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer. 1983; 51(10):1826-9. DOI: 10.1002/1097-0142(19830515)51:10<1826::aid-cncr2820511012>3.0.co;2-l. View

Kachnic L, Winter K, Myerson R, Goodyear M, Willins J, Esthappan J . RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2012; 86(1):27-33. PMC: 3619011. DOI: 10.1016/j.ijrobp.2012.09.023. View

Ali Z, Solomon E, Mann P, Wong S, Chan K, Taggar A . High dose rate brachytherapy in the management of anal cancer: A review. Radiother Oncol. 2022; 171:43-52. DOI: 10.1016/j.radonc.2022.03.019. View

Fish R, Sanders C, Adams R, Brewer J, Brookes S, DeNardo J . A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus. Lancet Gastroenterol Hepatol. 2018; 3(12):865-873. DOI: 10.1016/S2468-1253(18)30264-4. View

Rades D, Kopelke S, Bartscht T, Schild S, Tvilsted S, Kjaer T . Evaluation of Pre-radiotherapy Sleep Disorders in Patients With Rectal or Anal Cancer. Anticancer Res. 2021; 41(9):4439-4442. DOI: 10.21873/anticanres.15251. View

10.

Caravatta L, Mantello G, Valvo F, Franco P, Gasparini L, Rosa C . Radiotherapy with Intensity-Modulated (IMRT) Techniques in the Treatment of Anal Carcinoma (RAINSTORM): A Multicenter Study on Behalf of AIRO (Italian Association of Radiotherapy and Clinical Oncology) Gastrointestinal Study Group. Cancers (Basel). 2021; 13(8). PMC: 8071256. DOI: 10.3390/cancers13081902. View

11.

Poynter L, Raman R, Wegstapel H, Summers J, Lawes D . The prevalence and fate of the defunctioning stoma in patients with anal cancer: a regional experience following the ACT II trial. Colorectal Dis. 2017; 19(12):O407-O412. DOI: 10.1111/codi.13855. View

12.

Frakulli R, Buwenge M, Cammelli S, Macchia G, Farina E, Arcelli A . Brachytherapy boost after chemoradiation in anal cancer: a systematic review. J Contemp Brachytherapy. 2018; 10(3):246-253. PMC: 6052386. DOI: 10.5114/jcb.2018.76884. View

13.

Rao S, Guren M, Khan K, Brown G, Renehan A, Steigen S . Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(9):1087-1100. DOI: 10.1016/j.annonc.2021.06.015. View

14.

Muirhead R, Partridge M, Hawkins M . A tumor control probability model for anal squamous cell carcinoma. Radiother Oncol. 2015; 116(2):192-6. DOI: 10.1016/j.radonc.2015.07.014. View

15.

Cagetti L, Moureau-Zabotto L, Zemmour C, Ferre M, Giovaninni M, Poizat F . The impact of brachytherapy boost for anal canal cancers in the era of de-escalation treatments. Brachytherapy. 2023; 22(4):531-541. DOI: 10.1016/j.brachy.2023.03.004. View

16.

James R, Glynne-Jones R, Meadows H, Cunningham D, Myint A, Saunders M . Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol. 2013; 14(6):516-24. DOI: 10.1016/S1470-2045(13)70086-X. View

17.

. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet. 1996; 348(9034):1049-54. View

18.

DellAcqua V, Surgo A, Arculeo S, Zerella M, Bagnardi V, Frassoni S . Intensity-modulated radiotherapy (IMRT) in the treatment of squamous cell anal canal cancer: acute and early-late toxicity, outcome, and efficacy. Int J Colorectal Dis. 2020; 35(4):685-694. DOI: 10.1007/s00384-020-03517-x. View

19.

Tchelebi L, Eng C, Messick C, Hong T, Ludmir E, Kachnic L . Current treatment and future directions in the management of anal cancer. CA Cancer J Clin. 2021; 72(2):183-195. DOI: 10.3322/caac.21712. View

20.

Flam M, John M, Pajak T, Petrelli N, Myerson R, Doggett S . Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996; 14(9):2527-39. DOI: 10.1200/JCO.1996.14.9.2527. View